Dr. Thomas Frey served as Chief Operating Officer for Europe since June 2001 and has also served as Vice President of ICON Clinical Operations Europe from January 2000 to May 2001. He now holds the position of President ICON Development Solutions.

Thomas has over 22 years of experience in pharmaceutical research and development. He started his clinical career in 1987 with Hoechst Pharmaceuticals as a Clinical Project Manager, performing studies in metabolism, infectious disease, women’s health, and oncology. From 1995 to the end of 1999 he served as Senior Director of Clinical Development Europe at Hoechst Marion Roussel, adding cardiovascular, rheumatology, and CNS to his therapeutic experience.

Dr. Thomas Frey received his medical degree from the University of Heidelberg in 1980.

Dr. Mel Affrime joined ICON Development Solutions in April of 2006 as Sr. VP Global Clinical Pharmacology and was appointed CSO of the Division in August of 2006. Dr Affrime is responsible for ICON's global clinical pharmacology activities. 

Dr. Affrime has 33 years of demonstrated success in Global Pharmaceutical Development. He did a joint Residency in Hospital Pharmacy and Fellowship in Clinical Pharmacology with Marcus Reidenberg, MD at Temple University Medical College and Hospital from 1972 to 1974. He was appointed Senior Instructor of Pharmacology and Medicine at Hahnemann Medical College in 1976.

In 1977 he was Appointed Assistant Professor Pharmacology and Medicine and Co-Founded the Hahnemann Clinical Pharmacology Research Unit with David Lowenthal, MD. Dr. Affrime joined Hoechst-Roussel Pharmaceuticals as Associate Director of Clinical Research, Clinical Pharmacology in 1982 and in 1985 became Director Clinical Pharmacology at Schering-Plough Research Institute. From 1985 to 2002 he held positions of increasing responsibility and was appointed Vice President of Clinical Research, Clinical Pharmacology in 1994. From 1994 to 2002 he increased his scope of responsibilities at Schering-Plough to include Clinical Research Training and GCP Compliance. Dr. Affrime was appointed Global Head, Profiling Clinical Pharmacology at Novartis Pharmaceuticals in 2002.

Dr. Affrime received his Pharm.D. from The Philadelphia College of Pharmacy and Science in 1976.

Ms. Laura Johnson has over 20 years experience in the pharmaceutical and device industry. In 2009 she was appointed Senior Vice President Global Clinical Pharmacology Operations and Business Development. Previously she held the position of Vice President and General Manager of ICON Development Solutions – U.S., responsible for the growth and development of operations in the division’s Ellicott City, Maryland and Redwood City, California offices. Joining ICON in September 2003 when ICON acquired GloboMax LLC, Ms. Johnson has held positions with increasing responsibility including Director, Business Development, Senior Director, Business Development and then Vice President of Business Development for the global ICON Development Solutions division.

Prior to joining ICON, Laura's career experience includes 20 years in key sales, marketing and business management positions with GloboMax LLC and firms in the integrated voice/data technologies and surgical products/medical device business sectors.

Laura earned a BS degree from Virginia Tech and a Masters of Business Administration degree from Loyola College.

Ms. Gracelyn McDermott brings over 10 years of operational experience in leading teams, managing key client relationships and overseeing programs throughout the drug development life cycle. In 2009 she was named Vice President of Scientific Services, overseeing the global operations of Pharmacokinetics, Project Management, Biometrics, Clinical Operations, Customer Service, and Marketing & Information Management. In the prior two years, Ms. McDermott served as Vice President Business Development, responsible for building and maintaining an effective Business Development structure through leadership of the Sales, Proposals, Contracts, and Marketing. Joining ICON in September 2003 when ICON acquired GloboMax LLC, she has also held positions with increasing responsibility including Director, Project Management and Senior Director, Project Management, responsible for the division’s global Project Operations group.

Prior to joining ICON, Ms. McDermott oversaw drug development programs/projects encompassing multiple scientific disciplines such as preclinical, manufacturing, clinical development, pharmacokinetics/pharmacometrics, and regulatory affairs. This work spanned broad therapeutic areas, including oncology, cardiovascular, gastrointestinal, CNS, immunology, and ophthalmology.

Gracelyn holds an MBA from Johns Hopkins University and is a certified Project Management Professional (PMP) with advanced training in the application of project management knowledge, skills, techniques.

Dr. Mario Rocci has over 29 years of experience in the industry and joined ICON as the former CEO of Prevalere Life Sciences, Inc. (a wholly owned subsidiary of ICON plc) in 2008. He currently serves as Executive Vice President of Global Bioanalytical Sciences, overseeing ICON’s globally expanding Bioanalytical Sciences group, incorporating LC/MS/MS, Immunoassay and biomarker service offerings. Dr. Rocci’s vast experience includes positions such as Head of the Laboratory of Investigative Medicine and Research Associate Professor of Medicine at Thomas Jefferson University, where he was part of a team of Clinical Pharmacologists conducting Phase I-IV clinical studies on drugs undergoing development. Dr. Rocci was also a Clinical Associate Professor of Pharmacy Practice at the Philadelphia College of Pharmacy and Science.

Dr. Mario Rocci is well known throughout the pharmaceutical industry and has recently served as the 2004 President of the American Association of Pharmaceutical Scientists (AAPS), a professional society of over 12,000 members, having previously been elected to a three year term on the AAPS Board of Directors. He also serves on the Board of Directors for the International Pharmaceutical Federation (FIP) and is Chairman of the Board of the Product Quality Research Institute (PQRI).

Mario has authored over 125 scientific publications and has extensive experience in the pharmaceutical sciences and the regulatory requirements of the FDA. He has over 25 years of experience in the pharmaceutical industry.

Dr. Rocci earned a Ph.D. in Pharmaceutics and a B.S. in Pharmacy from the State University of New York at Buffalo.